Déjà vu Mab
Niche platform technology for life cycle maintenance of approved antibody drugs.
Platform method in engineering of the variable region leads to the second generation antibody drug with increased intrinsic target-binding activity, enhanced therapeutic efficacy, and an extended life cycle maintenance advantage.
If you are interested in Déjà vu Mab project, please feel free to contact us for further discussion!
Recombinant protein as a Pan Fc Receptor Interacting molecule
Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.
Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.
a Non-Antibody Biologics engineered for Blocking of SARS-CoV-2 Binding to ACE2.
Next generation CAR-T modules.
Niche platform technology for life cycle maintenance of approved antibody drugs.